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Abstract
Introduction—Intact neurocognition and early cognitive recovery during abstinence are 
important for substance use treatment outcome. Yet, little is known about them in the largest group 
of treatment seekers today, individuals with polysubstance use disorders (PSU). This study 
primarily contrasted PSU and individuals with an alcohol use disorder (AUD) on neurocognitive 
and inhibitory control measures and, secondarily, measured changes during abstinence in PSU.
Method—At one month of abstinence from all substances except tobacco, 36 PSU and 69 AUD 
completed neurocognitive assessments of executive function, general intelligence, auditory-verbal 
learning/memory, visuospatial learning/memory/skills, processing speed, working memory, fine 
motor skills, and cognitive efficiency. The groups were also assessed on inhibitory control 
measures of self-reported impulsivity, risk-taking, and decision-making. Seventeen PSU repeated 
the assessments after approximately four months of abstinence. All cross-sectional and 
longitudinal analyses included smoking status as a possible confound.
Results—At baseline, PSU performed significantly worse than AUD on auditory-verbal memory 
and on an inhibitory control measure of impulsivity. Polysubstance users showed trends to worse 
performance than AUD on general intelligence, auditory-verbal learning, and a decision-making 
task. Between one and four months of abstinence, PSU showed significant improvements on 
several neurocognitive and inhibitory control measures.
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Conclusions—Polysubstance users exhibit distinct differences in neurocognition and inhibitory 
control compared to AUD. Between one and four months of abstinence, neurocognition and 
inhibitory control improve in PSU. This neurocognitive recovery in some domains of abstinent 
PSU is influenced by smoking status. These results underscore the clinical value of select methods 
to augment neurocognitive recovery in PSU through appropriate interventions.
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Cognition; impulsivity; addiction; substance use disorders; longitudinal; recovery
INTRODUCTION
Treatment-seeking individuals with an alcohol use disorder (AUD) exhibit a range of 
neurocognitive (e.g., (Bates et al., 2002; Bell et al., 2016; Durazzo et al., 2006; Fein et al., 
1990; Oscar-Berman et al., 2014; Pennington et al., 2013; Sullivan et al., 2000) and 
inhibitory control (de Wit, 2009; Naim-Feil et al., 2014; Rupp et al., 2016) deficits. A recent 
review describes deficits related to working memory, visuospatial functions, inhibition, and 
executive-based functions such as mental flexibility, problem solving, divided attention 
(Bernardin et al., 2014), and cognitive control (Wilcox et al., 2014). AUD also exhibit worse 
cognitive efficiency than controls (Nixon et al., 1998). Of clinical relevance, inhibitory 
control deficits are greater in actively drinking alcoholics compared to controls (Moody et 
al., 2015; Vuchinich and Simpson, 1998) and they predict relapse in AUD (Rupp et al., 
2016). Research has also noted deleterious effects on neurocognition from chronic cigarette 
smoking, the most common substance use comorbidity in AUD, with rates in treatment-
seeking populations estimated at 60–90% (Durazzo et al., 2007; Hurt et al., 1994; Kalman et 
al., 2005; Romberger and Grant, 2004). Greater smoking severity in AUD predicted worse 
executive function (Glass et al., 2009), and smoking AUD performed worse than 
nonsmoking AUD on domains of auditory-verbal learning and memory, processing speed, 
cognitive efficiency, and working memory at one week and four weeks of abstinence 
(Durazzo et al., 2006; Pennington et al., 2013). Furthermore, smoking was shown to 
significantly hinder recovery of visuospatial learning and processing speed in AUD 
(Durazzo et al., 2014; Pennington et al., 2013).
A large proportion of treatment-seeking AUD have a concurrent substance use disorder (e.g., 
cocaine, amphetamines, marijuana, etc.), with 1.3 million people in the United States alone 
in 2013 (Kedia et al., 2007; Substance Abuse and Mental Health Services Administration, 
2013); therefore, this group is better described as “polysubstance users” (PSU), a term used 
in the literature to describe AUD who meet dependence criteria for additional substances 
(Abe et al., 2013; Murray et al., 2015; Pennington et al., 2015; Moreno-Lopez et al., 2012). 
Given the cognitive and inhibitory control deficits observed in AUD studies, it is not 
surprising that recently detoxified individuals with a substance use dependence diagnosis on 
any combination of heroin, alcohol, methamphetamine, and/or cannabis also performed 
worse than controls on several measures of executive function, including working memory, 
response inhibition, cognitive flexibility, and on inhibitory control measures of decision 
making (Moreno-Lopez et al., 2012). Individuals with both alcohol and stimulant 
dependence performed worse than controls on cognitive efficiency (Nixon et al., 1998), 
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complex attention and memory (Abi-Saab et al., 2005) as well as delayed discounting 
(Moody et al., 2015). Furthermore, poorer executive function in abstinent abusers of several 
substances has been related to the amount of cocaine and cannabis consumed (Fernandez-
Serrano et al., 2010b), suggesting clinically relevant consequences of chronic substance use.
Despite extensive research into the neurocognitive correlates of substance abuse, only few 
studies investigated neurocognition in PSU relative to the more extensively studied AUD, 
and then only on specific tasks. Short-term abstinent alcohol and stimulant dependent 
individuals performed worse than AUD on immediate and delayed recall conditions of a 
verbal memory task (Horner, 1997), but they did not differ from AUD on cognitive 
efficiency tasks of visual perception and category sorting (Nixon et al., 1998). Another study 
(Fernandez-Serrano et al., 2010a) found treatment-seeking abusers of multiple substances to 
perform moderately worse than AUD on executive function tasks of verbal fluency, working 
memory, planning, and multi-tasking.
Neurocognitive functions recover at least partially in AUD during sustained abstinence (e.g., 
(Bernardin et al., 2014)), and some evidence suggests that additional use of other substances 
by people with AUD impact neurocognitive recovery negatively (Schulte et al., 2014). Very 
few longitudinal studies have explicitly investigated changes in neurocognition or inhibitory 
control in abstinent PSU. In one study, individuals with a combined alcohol and cocaine use 
disorder demonstrated significant improvements on measures of immediate memory over six 
months of abstinence (Fein et al., 2002), while another described improvements in verbal 
short-term memory over three to four months of abstinence from multiple substances (Block 
et al., 2002).Intact neurocognition and inhibitory control are important for addiction 
treatment efficacy, retention (Aharonovich et al., 2006; Passetti et al., 2008; Streeter et al., 
2008; Bernardin 2014; Wilcox et al 2014), and maintenance of abstinence during treatment 
(de Wit, 2009; Rupp et al., 2016). Recent evidence has shown an association between better 
treatment response and longitudinal cognitive recovery in AUD (Bates et al., 2013). 
Identifying the specific neurocognitive and inhibitory control deficits that differentiate PSU 
and AUD may provide helpful insights into the specific clinical needs of this understudied 
(Connor et al., 2014), albeit highly prevalent population of PSU in substance use treatment 
centers today; such deficits potentially differ from those in the more extensively studied 
AUD population and therefore may require more tailored treatment approaches to increase 
treatment effectiveness. Our recent reports of different neurobiological abnormalities in 
AUD and a subset of the PSU cohort presented here (Abe et al., 2013; Murray et al., 2015) 
further supports the view that neurocognition may also differ between AUD and PSU 
populations. Accordingly, the main goals of this study were to determine the degree to which 
one-month-abstinent PSU and AUD differ on neurocognitive functioning and inhibitory 
control, and if cigarette smoking affects neurocognition in PSU, similar to what has been 
reported in AUD. A secondary goal was to explore if PSU exhibit improvements of 
neurocognitive function and inhibitory control between one and four months of abstinence 
from all substances except tobacco.
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METHOD
Participants
Thirty-six treatment-seeking polysubstance users (PSU; 25 smokers, 11 nonsmokers) and 69 
treatment-seeking alcohol users (AUD; 39 smokers, 30 nonsmokers) were recruited from 
substance abuse treatment programs at the San Francisco VA Medical Center and Kaiser 
Permanente for two different research projects on alcohol and substance use disorders. Table 
1 displays group demographics and relevant substance use characteristics. At baseline, PSU 
and AUD were abstinent from all substances except tobacco for approximately 29 days. 
Seventeen PSU (11 smokers, 6 nonsmokers; 16 male, 1 female) were restudied after 128 
± 29 days of sustained abstinence from all substances except tobacco. The 19 PSU not 
restudied at follow-up either self-reported relapse to any amount of substance use after 
baseline (including alcohol), were found to have relapse notes in their medical charts, or 
were lost to follow-up. All participants provided written informed consent according to the 
Declaration of Helsinki prior to participation. Study procedures were approved by the local 
Committee on Human Research.
All 105 participants met DSM-IV-TR criteria for an alcohol use disorder. In addition, all 36 
PSU met DSM-IV-TR criteria for at least one other substance use disorder: 27 (75%) with 
cocaine use disorder; 12 (33%) with amphetamine use disorder; 7 (19%) with cannabis use 
disorder; 5 (14%) with opioid use disorder; 1 (3%) with anxiolytic use disorder; and 1 (3%) 
with hallucinogen use disorder. Not considering cigarette smoking, nine PSU had two or 
more substance use disorders in addition to an alcohol use disorder. Specifically, of these 
nine, five participants met criteria for cocaine, amphetamine, and cannabis use disorder and 
one also met criteria for opioid and hallucinogen use disorders; two participants met criteria 
for amphetamine and cannabis use disorder (and one of them also met criteria for opioid use 
disorder); one participant met criteria for cocaine and opioid use disorders, and another met 
criteria for opioid and anxiolytic use disorders. Nonsmoking participants smoked fewer than 
20 cigarettes in their lifetime, with no cigarette use in the 10 years prior to study and no 
history of use of other tobacco products. Smoking participants were actively smoking at the 
time of the baseline assessment and smoked at least 10 cigarettes per day for 5 years or 
more, with no periods of smoking cessation greater than 1 month in the 5 years prior to 
enrollment. None of the PSU studied longitudinally changed their smoking status or severity 
between assessments.
Medical exclusion criteria were a current or past history of intrinsic cerebral tumors, human 
immunodeficiency virus or acquired immune deficiency syndrome, cerebrovascular 
accident, aneurysm, insulin dependent diabetes, chronic obstructive pulmonary disease, non-
alcohol related seizures, significant exposure to known neurotoxins, demylenating and 
neurodegenerative diseases, Wernicke-Korsakoff Syndrome, alcohol-induced persisting 
dementia, and traumatic brain injury resulting in loss of consciousness for more than 15 
minutes. Psychiatric exclusion criteria included schizophrenia or other thought disorders, 
bipolar disorder, dissociative disorders, posttraumatic stress disorder, obsessive compulsive 
disorder, and panic disorder (with or without agoraphobia), Hepatitis C, type-2 diabetes, 
hypertension, and unipolar mood disorders, were not exclusionary given their high 
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prevalence in substance use disorders (Mertens et al., 2003; Mertens et al., 2005; Moss et al., 
2010).
Psychiatric/Behavioral Assessment
At baseline (PSU and AUD) and follow-up (PSU only), each participant completed the 
Structured Clinical Interview for DSM-IV Axis I Disorder Patient Edition, Version 2.0, as 
well as questionnaires assessing depressive (Beck, 1978) and anxiety symptoms (State-Trait 
Anxiety Inventory, form Y-1 (state) and Y-2 (trait), STAI, (Spielberger et al., 1977)). 
Lifetime alcohol consumption was assessed at baseline with the Lifetime Drinking History 
semi-structured interview (Skinner and Sheu, 1982; Sobell et al., 1988). We derived the 
average number of standard alcoholic drinks (containing 13.6 g of ethanol) consumed per 
month, both one year before enrollment and over lifetime. Substance use history of PSU 
participants was assessed at baseline with a semi-structured interview developed in-house 
(Pennington et al., 2015). For each substance for which a PSU participant met criteria for a 
current or past substance use diagnosis, date of last use, frequency of use, and quantity of 
use (in grams) were gathered. All follow-up PSU maintained abstinence from all substances 
except tobacco. Abstinence was assessed with self-report, and confirmed via medical chart 
review, mandating negative urine toxicology and blood alcohol concentration tests 
conducted weekly as part of routine clinical care. The Fagerstrom Tolerance Test for 
Nicotine Dependence (Fagerstrom et al., 1991) was used to assess level of nicotine 
dependence, total years of cigarette smoking, and average number of daily cigarettes 
currently smoked.
Neurocognitive Assessment
A comprehensive neurocognitive battery was administered to each participant at baseline 
and again to PSU participants at follow-up. The battery included measures of executive 
function, general intelligence, auditory-verbal learning/memory, visuospatial learning/
memory/skills, processing speed, working memory, cognitive efficiency, and fine motor 
skills. Neurocognitive domains and constituent measures are presented in Table 2. Alternate 
forms for Brief Visuospatial Memory Test – Revised (BVMT-R) and California Verbal 
Learning Test-II (CVLT-II) were used at follow-up assessments for PSU. Premorbid verbal 
intelligence was estimated with the American National Adult Reading Test at baseline only 
(AMNART; (Grober and Sliwinski, 1991). All measures are well normed and commonly 
used in clinical and/or research settings (Strauss et al., 2006). In order to mitigate the 
potential for nicotine withdrawal effects on cognition, smokers were allowed to smoke ad 
libitum prior to the assessment and were allowed to take cigarette smoking breaks as 
requested.
Raw scores for neurocognitive measures, except the Luria-Nebraska Item 99 ratio, were 
converted to age-adjusted (i.e., BVMT-R, CVLT-II, Short Categories Test, Stroop Color–
Word Test, Wechsler Adult Intelligence Scale 3rd edition subtests) or age- and education-
adjusted (Wisconsin Card Sorting Test-64 variables; Trails A and B, Grooved Pegboard via 
Heaton Compendium Norms; (Heaton et al., 1991)) standardized scores via the 
accompanying normative data. Scaled scores and t-scores for all individual neurocognitive 
tests were transformed to z-scores to ease readability and interpretation of results using a 
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universal scaled score for neurocognitive measures. Scaled scores were subtracted by 10 (the 
mean of a scaled score) and divided by 3 (the standard deviation of a scaled score), while t-
scores were subtracted by 50 (the mean of a t-score) and divided by 10 (the standard 
deviation of a t-score). Neurocognitive domain scores are the arithmetic average of z-scores 
for all associated constituent measures. The cognitive efficiency domain consisted of all tests 
that were timed, or in which the time to complete the task influence the score achieved. For 
the Luria-Nebraska Item 99 measure, the number correct (possible range of scores: 0–8) was 
divided by time required to complete the task. This ratio was used due to the low ceiling for 
the number of correct responses (i.e., most participants achieved a score of six or better), 
resulting in a non-Gaussian distribution. Finally, the arithmetic average of z-scores for all 
individual neurocognitive measures was calculated to form a global neurocognition score for 
each participant.
Measures of Inhibitory Control (self-reported impulsivity, risk-taking, and decision-making)
Participants completed the Barratt Impulsivity Scale-11 (Patton et al., 1995), a self-report 
impulsivity questionnaire. The BIS-11 consists of 30 items rated on a scale of “1” (rarely/
never) to “4” (almost always) and provides total scores for nonplanning, attentional, motor, 
and total impulsivity. Participants also completed the Balloon Analogue Risk Task (BART) 
(Lejuez et al., 2002), a computerized risk-taking task in which participants pump up 
balloons to earn increasing monetary reward, with the potential for loss if a balloon 
overinflates and explodes. The BART yields a score for the adjusted number of pumps (i.e., 
the average number of pumps on all unexploded balloons), with higher scores indicating a 
higher propensity for risk-taking. Participants also completed the Iowa Gambling Task 
(IGT), a task of decision-making in which participants choose cards from four decks (two 
advantageous and two disadvantageous) with the goal of winning as much money as 
possible. The IGT yields a raw Net Total score for each participant based on his or her 
selections. Raw scores were converted to the demographically-corrected T scores, with 
higher T scores indicating better decision-making skills.
Statistical Analyses
All statistical analyses were performed with SPSS version 22 (IBM, 2012). Generalized 
linear models were used in all analyses, employing maximum likelihood parameter 
estimation, and followed up by pairwise group comparisons; a chi-square statistic (Wald) 
and corresponding p-value are generated for each parameter estimate. Three statistical 
models were tested: (1) primary cross-sectional models compared PSU to AUD at one 
month of abstinence and included fixed predictors of group (PSU, AUD); (2) secondary 
cross-sectional models investigated potential smoking effects in PSU and AUD at one month 
of abstinence and included fixed predictors of group (PSU, AUD), smoking status (Smoker, 
Nonsmoker) and the interaction term of group-by-smoking status; and (3) longitudinal 
models explored change in neurocognition within PSU between approximately 29 days (for 
n = 36 and n = 17 PSU at baseline) and 128 days of abstinence (n = 17 PSU at follow-up); 
predictors included smoking status (smoker, nonsmoker), time (baseline, follow-up), and the 
time-by-smoking status interaction term.
Schmidt et al. Page 6
J Clin Exp Neuropsychol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Patient characteristics of PSU and AUD at baseline were compared using univariate analysis 
of covariance for continuous variables and Fisher’s exact test for categorical variables. 
Polysubstance users and AUD differed in education, gender, AMNART, hepatitis C 
frequency, and proportion of individuals on prescribed psychoactive medication; these 
variables were entered as covariates in our generalized linear models comparing AUD and 
PSU at baseline. Potential covariates and interaction terms were trimmed from the final 
model when not predictive of the outcome variable. The proportion of study participants 
reporting a family history of alcohol problems was not significantly different between PSU 
and AUD (83% and 86%, respectively).
We accounted for the multiplicity of measures by correcting alpha levels via a modified 
Bonferroni procedure (Sankoh et al., 1997). This approach considers the mean correlation 
between variables and the number of tests in the adjustment of alpha levels. All alpha levels 
were adjusted for both traditional neurocognitive assessment (11 domains) and BIS-11 (3 
domains) and their average inter-correlation coefficients in primary and secondary models 
(neurocognitive domains: r = 0.429, BIS-11: r = 0.450) and in tertiary models 
(neurocognitive domains: r = 0.358, BIS-11: r = 0.495). The corresponding adjusted alpha 
levels for primary and secondary models were p ≤ 0.013 for neurocognitive domains and p ≤ 
0.027 for self-reported impulsivity. The corresponding adjusted alpha levels for tertiary 
models, which included PSU only, were p ≤ 0.011 for neurocognitive domains and p ≤ 0.017 
for BIS-11. Alpha levels for risk-taking (BART) and decision-making (IGT) were not 
adjusted as these are individual tasks measuring separate domains of executive function. 
Effect sizes (ES) for mean differences between groups (PSU versus AUD) were calculated 
with Cohen’s d (Cohen, 1988). We correlated cognitive functioning, risk-taking, decision-
making and self-reported impulsivity measures to alcohol use in PSU and AUD, and to 
cocaine, and marijuana use in PSU only at baseline. Since these were exploratory 
correlations, we chose a less restrictive alpha level of 0.05.
RESULTS
Characterization of study participants
Of the 36 PSU participants, 21 were African-American (58%), 9 Caucasian (25%), 4 Latino 
(11%), 1 Native American (3%), and 1 Polynesian/Pacific Islander (3%). Of the 69 AUD 
participants, 48 were Caucasian (71%), 9 Latino (13%), 7 African-American (10%), 3 
Native American (4%), 1 Asian (1%), and 1 declined to disclose ethnicity (1%). The PSU 
group had a smaller proportions of women (2% vs. 25%), and individuals on prescribed 
psychoactive medication (25% vs 62%) than AUD. The groups did not differ on mean age at 
baseline (PSU: 46 years; AUD: 48 years), rate of mood disorder, rate of hypertension, rate of 
smoking, drinking variables, mean BDI and STAI scores, mean number of days abstinent at 
baseline, or proportion of family members with alcohol problems. The PSU group started 
drinking any alcohol at age 14 (the AUD group at age 17), started drinking heavily (i.e., 
>100 standard alcoholic drinks per month) at age 22 (AUD at age 26), when both groups 
also started using cocaine, and both groups started smoking cigarettes daily at age 23. The 
PSU with other substance use disorders started using marijuana at age 16, opioids at age 26 
and amphetamines at age 37. See Table 1.
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Cross-sectional comparisons of neurocognition and inhibitory control between PSU and 
AUD
As shown in Table 3, and after co-varying for significant differences in AMNART, PSU 
performed significantly worse than AUD on auditory-verbal memory [x2(1) = 12.16, p < 
0.001, ES = 0.72], and PSU exhibited strong trends to worse performance than AUD on 
intelligence [x2(1) = 4.08, p = 0.043, ES = 1.05] and auditory-verbal learning [x2(1) = 4.62, 
p = 0.032, ES = 0.54]. For all other domains except fine motor skills, PSU showed 
numerically lower scores than AUD with effect sizes up to 0.76 but no statistically 
significant group differences after covariate correction (where indicated). When smoking 
status was included as a factor in the cross-sectional group analyses of neurocognitive 
domains, neither significant group-by-smoking interactions nor main effects of smoking 
were observed. In addition, gender was not a significant predictor of neurocognitive 
performance at one month of abstinence, except for fine motor skills which were worse in 
female than male substance users. Removing the two women from our PSU analyses did not 
significantly change any of our results.
Polysubstance users exhibited trends to worse decision-making (IGT) than AUD [x2(1) = 
3.64, p = 0.056, ES = 0.33]; the groups were not significantly different on risk-taking 
(BART). No significant group-by-smoking interactions or main effects for smoking were 
observed on either IGT or BART.
Polysubstance users self-reported significantly higher BIS-11 total (p = 0.002, ES = 0.36) 
and nonplanning impulsivity, a measure of cognitive control, than AUD (p = 0.001, ES = 
0.48), and being on a prescribed psychoactive medication significantly predicted higher total 
(p = 0.001) and nonplanning (p = 0.005) impulsivity. With smoking status included in the 
analyses, no significant group-by-smoking interactions were observed for any of the BIS-11 
measures. However, self-reported motor impulsivity showed a trend for a group-by-smoking 
interaction [x2(1) = 3.259, p = 0.071], a significant main effect for group [x2(1) = 2.005, p = 
0.006], and a trend for a smoking effect [x2(1) = 1.499, p = 0.066]. Follow-up pairwise 
comparisons showed significantly higher motor impulsivity in smoking PSU compared to 
both smoking (p = 0.006) and nonsmoking AUD (p = 0.030).
Longitudinal change of neurocognition and inhibitory control in abstinent PSU
Between baseline and follow-up, neurocognitive functions in abstinent PSU improved 
markedly in the following domains: general intelligence, cognitive efficiency, executive 
function, working memory, and visuospatial skills (all p < 0.005), and weaker improvements 
were observed for global cognition (p = 0.016) and processing speed (p = 0.051). Abstinent 
PSU did not change significantly in the domains of learning and memory (both auditory-
verbal and visuospatial) or fine motor skills. Preliminary analyses indicate that the lack of 
significant changes in the domains of visuospatial memory and fine motor skills were related 
to significant time-by-smoking status interactions (both p < 0.001), where only nonsmokers 
increased on fine motor skills and only smokers improved on visuospatial memory. The 
BART scores increased significantly with abstinence (p < 0.005), whereas the IGT scores 
did not change during abstinence. Self-reported total and motor impulsivity (BIS-11) 
decreased significantly with abstinence (both p < 0.001) and the nonplanning score tended to 
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decrease (p = 0.028). The following changes were observed when restricting our 
longitudinal analysis to only those 17 PSU with baseline and follow-up data: general 
intelligence, executive function, working memory (all p < 0.05), visuospatial skills (p = 
0.054), global cognition (p = 0.011), and processing speed (p = 0.134). The 19 PSU not 
studied longitudinally (shown and presumed to have relapsed) differed from our abstinent 
PSU restudied on lifetime years of cocaine use (24 vs. 15 years in abstainers, p = 0.009). 
PSU not restudied performed significantly worse at baseline than abstinent PSU on cognitive 
efficiency, processing speed, and visuospatial learning (all p < 0.05). Furthermore, they did 
not differ significantly on years of education, AMNART, tobacco use severity, and 
proportions of smokers or family members with problem drinking, or the proportion of 
individuals taking a prescribed psychoactive medication.
Associations of substance use measures with neurocognition and inhibitory control
In PSU, more lifetime years drinking correlated with worse performance on domains of 
cognitive efficiency, executive function, intelligence, processing speed, visuospatial skills, 
and global cognition (all p < 0.05, r > −0.48). More cocaine consumed per month over 
lifetime correlated with worse performance on executive function (p = 0.03, r = −0.42) and 
greater attentional impulsivity (p = 0.04, r = 0.37). More marijuana consumed per month 
over lifetime correlated with worse performance on fine motor skills (p = 0.04, r = −0.73) 
and tended to correlate with higher BIS-11 motor impulsivity (p = 0.09, r = 0.64); in 
addition, more marijuana use in the year preceding the study correlated with higher 
nonplanning (p = 0.03, r = 0.77) and total (p = 0.07, r = 0.66) impulsivity. Earlier onset age 
of marijuana use correlated with higher nonplanning impulsivity (p < 0.01; r = −0.88) and 
worse visuospatial learning (p = 0.03; r = −0.75). Interestingly, more lifetime years of 
amphetamine use correlated with better performance on fine motor skills, executive 
function, visuospatial skills, and global cognition (all p < 0.05, r < 0.82).
Similar to the associations found in PSU, more lifetime years drinking in AUD correlated 
with worse performance on cognitive efficiency, visuospatial skills, and global cognition (all 
p ≤ 0.05, r > −0.40), and worse performance on visuospatial memory correlated with greater 
monthly alcohol consumption averaged over the year preceding assessment (p = 0.01, r = 
0.31) and over lifetime (p = 0.05, r = 0.24). In addition, longer duration of alcohol use in 
AUD was related to worse auditory-verbal learning and memory (both p ≤ 0.04, r ≥ −0.28). 
Earlier age of onset of heavy drinking in AUD was associated with worse decision-making 
(IGT) (p = 0.05, r = −0.25).
DISCUSSION
Our primary aim was to compare neurocognitive functioning and inhibitory control in one-
month-abstinent PSU and AUD. Polysubstance users at one month of abstinence showed 
decrements on a wide range of neurocognitive and inhibitory control measures compared to 
normed measures. The decrements in neurocognition ranged in magnitude from 0.2 
(auditory-verbal learning) to 1.4 (visuospatial learning) standard deviation units below a z-
score of zero, with deficits >1 standard deviation below the mean observed for visuospatial 
memory and visuospatial learning. In comparisons to AUD, PSU performed significantly 
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worse on measures assessing auditory-verbal memory, and tended to perform worse on 
measures of auditory-verbal learning and general intelligence. Chronic cigarette smoking 
status did not significantly moderate cross-sectional neurocognitive group differences at 
baseline. In addition, PSU exhibited worse decision-making and higher self-reported 
impulsivity than AUD (the latter driven by higher motor impulsivity particularly in smoking 
PSU), signaling potentially greater risk of relapse for PSU than AUD (Schulte et al., 2014). 
Being on a prescribed psychoactive medication related to higher self-reported impulsivity in 
PSU. For both PSU and AUD, more lifetime years drinking were associated with worse 
performance on global cognition, cognitive efficiency, general intelligence, and visuospatial 
skills. Within PSU only, greater substance use quantities related to worse performance on 
executive function and fine motor skills, as well as to higher self-reported impulsivity.
Neurocognitive deficits in AUD have been described extensively. However, corresponding 
reports in PSU are rare and very few studies compared PSU to AUD during early abstinence 
on such a wide range of neurocognitive and inhibitory control measures as administered here 
(Schulte et al., 2014). To our knowledge, no previous reports have specifically shown PSU to 
perform worse than AUD on domains of auditory-verbal learning and general intelligence at 
one month of abstinence. Our studies confirmed previous findings of worse auditory-verbal 
memory (Horner, 1997) and inhibitory control (Moody et al., 2015) in individuals with a 
comorbid alcohol and stimulant use disorder compared to those with an AUD, and findings 
of no differences between the groups on measures of cognitive efficiency (Nixon et al., 
1998). Some of the cross-sectional neurocognitive and inhibitory control deficits described 
in this PSU cohort are associated with previously described morphometric abnormalities in 
primarily prefrontal brain regions of a subsample of this PSU cohort with neuroimaging data 
(Mon et al., 2014; Pennington et al., 2015). Our neurocognitive findings also further 
complement studies in subsamples of this PSU cohort that exhibit prefrontal cortical deficits 
measured by magnetic resonance spectroscopy (Abe et al., 2013) and cortical blood flow 
(Murray et al., 2015).
Our secondary aim was to explore if PSU demonstrate improvements on neurocognitive 
functioning and inhibitory control measures between one and four months of abstinence 
from all substances except tobacco. Polysubstance users showed significant improvements 
on the majority of cognitive domains assessed here, particularly cognitive efficiency, 
executive function, working memory, self-reported impulsivity, but an unexpected increase 
in risk-taking behavior (BART). By contrast, no significant changes were observed for 
learning and memory domains, which were also worst at baseline, resulting in (residual) 
deficits in visuospatial learning and visuospatial memory at four months of abstinence of 
more than 0.9 standard deviation units below a z-score of zero. There were also indications 
for significant time-by-smoking status interactions for visuospatial memory and fine motor 
skills, however these analyses have to be interpreted with caution and considered very 
preliminary, considering the small sample sizes of smoking and nonsmoking PSU at follow-
up. Nevertheless, the demonstrations of cognitive recovery in abstinent PSU, and potential 
effects of smoking status on such recovery, are consistent with our observations of 
corresponding recovery in abstinent AUD (Durazzo et al., 2007; Durazzo et al., 2014; 
Pennington et al., 2013). The 19 PSU not studied at follow-up (and confirmed or presumed 
to have relapsed after baseline) differed significantly from abstinent PSU at baseline on 
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several important variables: they had more years of cocaine use over lifetime, and performed 
worse on cognitive efficiency, processing speed, and visuospatial learning. As such, these 
differences should be tested as potential predictors of relapse in future larger studies.
Several factors limit the generalizability of our findings. Our cross-sectional sample size was 
modest (due to funding restrictions) and therefore our longitudinal sample of abstinent PSU 
was small; as not uncommon in clinical samples, about half of our PSU cohort relapsed (or 
were lost to follow-up) between baseline and follow-up, a rate comparable to what has been 
reported elsewhere (McLellan et al., 2000). This made us focus our longitudinal results 
reporting on the main effects of time (independent of the effects of smoking status) and to 
de-emphasize the reporting of time-by-smoking status interactions. Larger studies are 
needed to examine the potential effects of smoking status and gender on neurocognitive 
recovery during abstinence from substances. The study sample was drawn from treatment 
centers of the Veterans Affairs system in the San Francisco Bay Area and a community-
based healthcare provider, and the ethnic breakdown of the study groups was different (with 
PSU being mostly African American and the AUD group predominantly Caucasian). 
Therefore, our sample may not be entirely representative of community-based substance use 
populations in general. Although preliminary, the within subject statistics are meaningful as 
they are more informative for assessing change over time than larger cross-sectional studies 
at various durations of abstinence. In addition, premorbid biological factors (e.g., genetic 
vulnerability to the effects of substance use, pulmonary, and cerebrovascular dysfunction) 
and other behavioral factors (e.g., diet, nutrition, and exercise) not assessed in this study may 
have influenced cross-sectional and longitudinal outcome measures. Nonetheless, our study 
is important and of clinical relevance in that it describes deficits in neurocognition and 
inhibitory control of detoxified PSU that are different from those in AUD, and that appear to 
recover during abstinence from substances, potentially as a function of smoking status.
Our cross-sectional and longitudinal findings are valuable for improving current substance 
use rehabilitation programs. The higher impulsivity and reduced cognitive abilities 
(including decision making) of PSU compared to AUD, likely the result of long-term 
comorbid substance use, and the lack of improvements in learning and memory during 
abstinence indicate a potentially reduced ability of PSU to acquire new cognitive skills 
necessary for remediating maladaptive behavioral patterns that impede successful recovery. 
As such, PSU may require a post-detox treatment approach that accounts for these specific 
deficits relative to AUD. Our results show that PSU able to maintain abstinence for 4 months 
had less total lifetime years of cocaine use and performed better on cognitive efficiency, 
processing speed and visuospatial learning than those PSU not restudied (shown and 
presumed to have relapsed); these variables may therefore be valuable for predicting future 
abstinence or relapse in PSU. Additionally, and if confirmed in larger studies, our 
preliminary results on differential neurocognitive change in smoking and nonsmoking PSU 
may inform a treatment design that addresses the specific needs of these subgroups (i.e., 
smoking cessation) within this largely understudied population of substance users. 
Potentially, concurrent treatment of cigarette smoking in treatment-seeking PSU may also 
help improve long-term substance use outcomes, just as recently proposed for treatment-
seeking individuals with AUD (Weinberger et al., 2015). Finally, our findings on 
neurocognitive improvement in PSU imply that cognitive deficits are to some extent a 
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consequence of long-term substance use (i.e., state not trait) (Grant and Chamberlain, 2014), 
which have the potential for remediation with abstinence. This information is of clinical 
relevance and of psychoeducational value for treatment providers and treatment-seeking 
PSU alike.
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Table 1
Demographics, clinical, and substance use variables for PSU and AUD groups at baseline (mean ± standard 
deviation)
PSU AUD
Number of participants 36 69
Race/Ethnicity n (%)
  African American 21 (58) 7 (10)
  Asian 0 (0) 1 (1)
  Caucasian 9 (25) 48 (71)
  Latino 4 (11) 9 (13)
  Native Amer./Aleutian 1 (3) 3 (4)
  Polynesian/Pac. Island 1 (3) 0 (0)
  Other 0 (0) 1 (1)
Gender m (f) 34 (2)* 52 (17)*
Hypertension n (%) 7 (19) 19 (28)
Hepatitis C+ n (%) 7 (19)* 4 (6)*
Being on prescribed
psychoactive medication n (%) 9 (25)
* 43 (62)*
Mood disorder n (%) 7 (19) 17 (25)
Substance-induced mood
disorder n (%)
3 (8) 6 (9)
FH of alcohol problems n (%) 30 (83) 59 (86)
Smoking status n (%) 25 (69) smokers;
11 (31) nonsmokers
39 (57) smokers;
30 (43) nonsmokers
AMNART 105.3 ± 9.1* 115.3 ± 9.1*
Education (years) 12.6 ± 1.3* 14.5 ± 2.3*
Age at baseline (years) 46.3 ± 10.1 47.8 ± 10.8
BDI 11.2 ± 7.9 12.3 ± 8.3
STAI (State) 34.6 ± 11.0 35.2 ± 11.3
STAI (Trait) 34.8 ± 11.0 35.0 ± 11.2
FTND total 4.4 ± 1.4 4.0 ± 1.6
FTND lifetime highest 15.6 ± 6.5 16.7 ± 8.1
FTND years daily smoking 23.2 ± 12.6 25.3 ± 10.3
1 year average drinks/month 233 ± 232 302 ± 173
Lifetime average drinks/month 211 ± 191 182 ± 108
Lifetime years drinking 31.2 ± 9.9 30.8 ± 11.1
Years heavy drinkinga 19.2 ± 10.7 18.5 ± 10.7
Onset heavy drinkinga (age) 22.1 ± 8.9 25.5 ± 8.8
Abstinent from alcohol at
baseline (days)
29.8 ± 8.4 28.8 ± 9.7
Years cocaine use (n=27) 18.4 ± 10.6 n/a
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PSU AUD
Onset cocaine use (age) 22.0 ± 7.8 n/a
Years amphetamine use (n=12) 12.8 ± 8.1 n/a
Onset amphetamine use (age) 37.3 ± 11.8 n/a
Years marijuana use (n=7) 26.9 ± 13.4 n/a
Onset marijuana use (age) 15.6 ± 7.5 n/a
Years opioid use (n=5) 6.3 ± 5.1 n/a
Onset opioid use (age) 26.2 ± 13.7 n/a
*
significantly different at p ≤ 0.05
aheavy drinking defined as >100 alcoholic drinks/month in men and >80 alcoholic drinks/month in women
AMNART, American National Adult Reading Test; FTND, Fagerstrom Tolerance Test for Nicotine Dependence; BDI, Beck Depression Inventory; 
STAI, State-Trait Anxiety Inventory; FH, family history
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Table 2
Neurocognitive domains and their constituent measures
Neurocognitive Domain Constituent Measures
Executive functions • Short Categories Test (Wetzel and Boll, 1987)
• Stroop Test, color-word subtest (Golden, 1978)
• Trail Making Test B (Reitan and Wolfson, 1985)
• Wechsler Adult Intelligence Scale 3rd Edition (WAIS-III) Similarities (Wechsler, 1997)
• Wisconsin Card Sorting Test-64 (WCST-64): Computer Version 2-Research Edition non-
perseverative errors, perseverative errors, perseverative responses (Kongs et al., 2000)
General intelligence • Ward-7 Full Scale IQ (Axelrod et al., 2001), based on the following WAIS-III subtests: 
Arithmetic, Block Design, Digit Span, Digit Symbol, Information Picture Completion
Auditory-verbal learning • California Verbal Learning Test-II (CVLT-II) Immediate Recall trials 1–5 (Delis et al., 
2000)
Auditory-verbal memory • CVLT-II Short and Long Delay Free Recall (Delis et al., 2000)
Visuospatial learning • Brief Visuospatial Memory Test-Revised (BVMT-R) Total Recall on learning trials 1–3 
(Benedict, 1997)
Visuospatial memory • BVMT-R Delayed Recall (Benedict, 1997)
Visuospatial skills • WAIS-III Block Design (Wechsler, 1997)
• Luria-Nebraska Item 99 (Golden et al., 1978)
Processing speed • WAIS-III Digit Symbol (Wechsler, 1997)
• WAIS-III Symbol Search (Wechsler, 1997)
• Stroop, color-word subtests (Golden, 1978)
• Trail Making Test A (Reitan and Wolfson, 1985)
Working memory • WAIS-III Arithmetic (Wechsler, 1997)
• WAIS-III Digit Span (Wechsler, 1997)
Fine motor dexterity • Grooved Pegboard Test (Lafayette Instrument)
Cognitive efficiency • This domain consisted of all tests that were timed, or where the time to complete the task 
influenced the score obtained:
– Luria-Nebraska Item 99 (Golden et al., 1978)
– Stroop word, color, and color-word tests (Golden, 1978)
– Trail Making Test A and B (Reitan and Wolfson, 1985)
– WAIS-III Arithmetic, Block Design, Digit Symbol, Picture 
Completion, and Symbol Search (Wechsler, 1997)
Neurocognitive domains are the arithmetic averages of the z-scores for all constituent measures
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Table 3
Measures for neurocognitive domains (Z-scores) and inhibitory control (raw mean ± standard deviation) in 
PSU and AUD groups at baseline
Neurocognitive
Domain/Measure
PSU
n = 36
AUD
n = 69
Effect size#
Global Cognition$ −0.58 ± 0.53 −0.12 ± 0.68 0.76
AV learning$ −0.23 ± 0.95 0.28 ± 0.94 0.54*
AV memory$ −0.43 ± 0.95 0.25 ± 0.93 0.72**
Cognitive efficiency −0.44 ± 0.59 −0.06 ± 0.67 0.60
Executive function$ −0.36 ± 0.67 −0.16 ± 0.64 0.31
Fine motor skills$$ −0.68 ± 0.98 −0.69 ± 1.16 0.01
Intelligence$ −0.57 ± 0.71 0.26 ± 0.87 1.05*
Processing Speed$ −0.41 ± 0.62 −0.09 ± 0.67 0.50
VS memory$ −1.10 ± 1.05 −0.89 ± 1.27 0.18
VS skills$ −0.59 ± 0.88 −0.14 ± 1.02 0.47
VS learning$ −1.35 ± 1.18 −0.89 ± 1.31 0.37
Working memory$ −0.47 ± 0.79 0.11 ± 0.82 0.72
BIS-11 total impulsivity$$$ 68.22 ± 10.5 64.52 ± 10.3 0.36**
  BIS-11 nonplanning$$$ 27.6 ± 4.1 25.4 ± 5.0 0.48**
  BIS-11 attentional$$$ 16.8 ± 4.2 16.6 ± 4.3 0.05
  BIS-11 motor$$$ 23.8 ± 4.7 22.6 ± 3.8 0.29
IGT (total T-score)$$$$ 46.6 ± 7.1 49.3 ± 9.5 0.33*
BART (adjusted pumps) 584 ± 227 612 ± 215 0.13
*
PSU show trends to worse performance than AUD after covariate correction
**
PSU perform significantly worse than AUD after covariate correction adjusted alpha: neurocognitive domains (p ≤ 0.013); BIS-11 (p ≤ 0.027); 
IGT and BART (p = 0.05)
#Cohen’s d before covariate correction (weak ≤ 0.30; moderate = 0.31–0.50; strong ≥ 0.51)
$AMNART;
$$gender;
$$$psychoactive medication;
$$$$
Hepatitis C+;: significant covariate used in group comparison
AV: auditory-verbal; VS: visuospatial; BIS-11: Barratt Impulsivity Scale; IGT: Iowa Gambling Task; BART: Balloon Analogue Risk Task
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